Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
S Walzer,1 K Travers,2 S Rieder,3 E Erazo-Fischer,3 D Matusiewicz41MArS Market Access and Pricing Strategy UG (hb), Weil am Rhein, Germany; 2United Biosource Corporation, Lexington, USA; 3Alcimed GmbH, Cologne, Germany; 4Institute for Health Care Management and Research, Faculty of Economics and Bus...
Main Authors: | Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-05-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | http://www.dovepress.com/homozygous-familial-hypercholesterolemia-hofh-in-germany-an-epidemiolo-a12937 |
Similar Items
-
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
by: Laura D’Erasmo, et al.
Published: (2021-09-01) -
Lomitapide in the long-term real-world management of HoFH – effectiveness, tolerability, and hepatic safety from the Pan-European study
by: J. Cegla, et al.
Published: (2022-10-01) -
Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry
by: Marina Cuchel, et al.
Published: (2023-05-01) -
Case report: Therapy adherence, MTTP variants, and course of atheroma in two patients with HoFH on low-dose, long-term lomitapide therapy
by: Meral Kayikcioglu, et al.
Published: (2023-01-01) -
Correction to: Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights from the CASCADE FH Registry
Published: (2023-06-01)